Important NIDA Funding Opportunity: Opioid-Induced Respiratory Depression

The Lung Association wanted to make you aware of an important funding opportunity from the National Institute on Drug Abuse (NIDA). According to the NIH, more than 2 million Americans have opioid use disorder. Millions more misuse opioids, taking medications longer or in higher doses than prescribed. NIDA has a new funding program that supports research to provide new strategies for the prevention and treatment of opioid misuse and addiction in order to help people with opioid use disorder achieve and maintain a meaningful and sustained recovery.

NIDA is specifically interested in funding grants to further our understanding of the very important issue of Opioid-Induced Respiratory Depression. The specific RFA can be found at: RFA-DA-19-002. Since this is a vital issue related to respiratory health and disease, the Lung Association wanted to make you aware of this rapid turnaround funding mechanism. The goal of this funding mechanism is to support the discovery and development of medications to prevent and treat opioid use disorders (OUD) and overdose.

This opportunity is unique in that NIDA is not bound by the three standard NIH submission dates per year. The institute is a conducting rolling submission and review process. Applications received by January 1, 2019 will be reviewed by February 22, 2019. Those received by April 1, 2019 will be reviewed by May 22, 2019. There are a number of additional dates through January 2020.

We hope you will consider and share this new opportunity.